Cat. No. 2989
Alternative Names: Prostaglandin I2, Prostacyclin
Chemical Name: (5Z,13E,8R,9S,11R,12R,15S)-6,9-Epox
Biological ActivityEndogenous prostanoid that is a potent agonist at IP prostanoid receptors. Inhibits platelet aggregation and induces vasodilation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Kobzar et al (2001) Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets. Cell.Physiol.Biochem. 11 279. PMID: 11684817.
Oliva and Nicosia (1987) PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharmacol.Res.Comm. 19 735.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Epoprostenol include:
Armstrong et al (2015) Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood 126 e11. PMID: 26215112.
Do you know of a great paper that uses Epoprostenol from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Epoprostenol, supplier, Endogenous, IP, receptors, agonists, Prostanoid, prostaglandins, prostacyclins, eicosanoids, Tocris Bioscience, Prostanoid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally available
April 10 - 13, 2017